Regulatory approval
Published by the Health Canada.
Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
This is written in the approval document as:
GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HC (1) | PDGFRA rearrangements | Myelodysplastic Syndromes | Imatinib | |
| HC (1) | PDGFRB rearrangements | Myelodysplastic Syndromes | Imatinib | |
| HC (1) | PDGFRA rearrangements | Myeloproliferative Neoplasm | Imatinib | |
| HC (1) | PDGFRB rearrangements | Myeloproliferative Neoplasm | Imatinib |